This is the authors' abstract. We don't add key points for this paper.
Neoadjuvant AI treatment markedly improved surgical outcomes. Ki67 and PEPI data demonstrated that the three agents tested are biologically equivalent and therefore likely to have similar adjuvant activities. LumA tumors were more likely to have favorable biomarker characteristics after treatment; however, occasional paradoxical increases in Ki67 (12% of tumors with > 5% increase after therapy) suggest treatment-resistant cells, present in some LumA tumors, can be detected by post-treatment profiling.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
Ellis et al. (2011) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: